| |
GeneSuites is the development manager for Catalyst BioCampus in North Carolina which is on track to support biomanufacturing by 2024. Learn more.
|
|
Today's Big NewsNov 28, 2022 |
| By Nick Paul Taylor Concerns are mounting about the safety of Eisai and Biogen’s Alzheimer’s disease prospect lecanemab. Ahead of the presentation of the full phase 3 dataset on Tuesday, Science has reported on the death of a second recipient of the anti-amyloid antibody who suffered a brain hemorrhage. |
|
|
|
By Ben Adams Pfizer’s chief executive Albert Bourla is in hot water for claims he made during a BBC interview late last year about his then-unapproved COVID vaccine for younger kids. The claims have been branded “misleading” and “overly promotional," according to a press report. |
By Conor Hale Bionaut Labs’ fantastic voyage continues, with $43.2 million in new venture capital funding to help build up its tiny robots into machines capable of swimming through the human body. |
By Annie Burky As winter sets in and Americans begin a season of travel, the Biden administration, HHS and CMS are embarking on a new concerted push to increase COVID-19 vaccinations. |
|
Tuesday, December 6, 2022 | 12pm ET/9am PT Biopharma customers are now demanding that the vendor industry work collaboratively to connect their scientific workflows. This webinar will provide valuable insights for biopharmaceutical scientists, lab directors, IT professionals, and life science vendors. Register now.
|
|
By Max Bayer Hansa Biopharma says new phase 2 data of the company's one-trick-pony transplant treatment found that it beat standard of care in treating antibody-mediated resistance following a kidney transplant. The company is also testing the med prior to treatment of a couple of budding gene therapies. |
By Fraiser Kansteiner On Monday, Sanofi officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-feet) facility will host around 500 employees and is designed around “new hybrid ways of working,” the company explained. |
By Max Bayer The road for anti-TIGIT therapies has been bumpy but Gilead and Arcus are teasing new data they hope will alleviate concerns. The two companies say that an updated interim analysis shows that combination therapies including their own TIGIT are showing improvements compared to an anti-PD-L1 monotherapy. |
By Dave Muoio More than a dozen nonprofit health systems have released their financials for the third calendar quarter. Labor, inflationary and payer mix struggles hit harder for some than others, resulting in operating margins ranging anywhere from −5.1% to 7.7%. |
By Conor Hale The SIGNA Experience system combines AI- and deep learning-powered programs to help staff ready scanners and obtain clear diagnostic images as fast as possible. |
By Angus Liu Following a biopharma industry trend, Kyowa Kirin is narrowing its focus by offloading some mature medicines. Besides its own emphasis on novel medicines, the company also said COVID-19 and increased geopolitical risks have created a “challenging business environment.” |
By Paige Minemyer The Google Search team has quietly rolled out multiple features for its search engine that aim to make it easier for users to access key information about obtaining Medicaid and Medicare benefits, as well as which doctors locally accept those types of coverage. |
By Gabrielle Masson Escient Pharmaceuticals has scored $120M, a much heftier sum than its $77.5M series B from a few years ago and once again snagging support from Big Pharma Sanofi’s VC arm. |
By Conor Hale Aidoc obtained two new clearances from the FDA for its artificial intelligence programs that help analyze CT scans to spot dangerous conditions and alert providers. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we discuss the challenges companies face in trying to provide healthcare coverage for their workers. We also talk about how to fix the broken healthcare system. |
|
|---|
|
|
|
Tuesday, December 7th, 2022 | 10am ET/7am PT In this presentation we’ll review how we established GOCHO™ cells from an adherent CHO-K1 cell line to meet current industry standards, how the choice of cloning media drove cell culture media choices for the entire cell-line development process, and more. Register now.
|
|
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
| WhitepaperLearn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| WhitepaperThis paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
| Executive Summary Strategies to help scale-up for commercial manufacturing are critical to getting cell and gene therapies to patients as more advanced therapies reach late-stage clinical studies and regulatory decisions. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
